Merck stock slides 3.5% as insider sale filing lands; traders eye next FDA deadline
Merck & Co shares dropped 3.5% to $117.65 Monday, underperforming a tech-led market rebound. EVP Jennifer Zachary sold 121,573 shares at a weighted-average $119.15 after exercising options, according to an SEC filing. The FDA is expected to rule Feb. 20 on expanding Keytruda’s use for ovarian cancer. Merck remains reliant on Keytruda as older drugs face increased competition.